DS
SURF

David Shaw’s Surface Oncology, Inc. Common Stock SURF Stock Holding History

David Shaw’s Portfolio SURF Stock Details SURF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-22,605
Closed -$176K – 5106
2021
Q1 		$176K Sell
22,605
-27,074
-54% -$271K ﹤0.01% 3872
2020
Q4 		$459K Buy
+49,679
New +$432K ﹤0.01% 3429

Other funds holding SURF

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

David Shaw's SURF Position: Q2 2021 in Review

David Shaw sold out of Surface Oncology, Inc. Common Stock (SURF) in Q2 2021, closing a stake of 22,605 shares — an estimated $176K sold.

David Shaw first reported a position in SURF in Q4 2020 and held it in 2 quarters. The position peaked at $459K in Q4 2020. 96 funds tracked by Wall St. Rank hold SURF as of Q2 2021.

  • David Shaw reported no remaining Surface Oncology, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • David Shaw sold 22,605 Surface Oncology, Inc. Common Stock shares in Q2 2021, an estimated $176K.
  • David Shaw first reported a position in Surface Oncology, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • David Shaw's Surface Oncology, Inc. Common Stock position peaked at $459K in Q4 2020.
  • 96 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q2 2021.

Based on D.E. Shaw & Co's 13F filing for Q2 2021, filed 16 Aug 2021.